LONDON (Alliance News) - hVIVO PLC on Thursday described 2018 as a "transitional" year as it posted a widened annual loss on impairment charges.For 2018, the drug discovery posted Read More
LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Thursday.----------FTSE 100 - up 2.5%. The supermarket chain revealed a a Read More
LONDON (Alliance News) - hVIVO PLC on Thursday said it achieved the primary endpoint in a phase II study of FLU-v, a vaccine candidate for influenza.The company said that the study showed a Read More
LONDON (Alliance News) - hVIVO PLC said Wednesday preliminary results from the first in-man study of AGS-v, a proposed mosquito-borne disease vaccine, met primary objectives and endpoints safety a Read More
LONDON (Alliance News) - hVIVO PLC said Thursday that increased revenue generation and ongoing costs savings led to a narrowed loss for the first half.The clinical development services also Read More
LONDON (Alliance News) - Shares in hVIVO PLC rose on Monday after the scientific research company announced positive results from the study of its flu vaccine.Shares were trading up 25% at Read More
LONDON (Alliance News) - Clinical development and drug discovery business hVIVO PLC said Thursday its loss narrowed in 2017 as Chief Executive Kym Denny stepped aside for Executive Chairman Trevor Read More
LONDON (Alliance News) - hVIVO PLC said on Monday it received encouraging initial results from a Phase IIb study examining FLU-v as a potential universal vaccine against is by Read More
